Opus Point Partners, a biotech hedge fund, was founded by Michael S. Weiss and Dr. Lindsay A. Rosenwald in 2009. Prior to launching Opus Point Partners, Michael Weiss and Lindsay Rosenwald had worked together between 1993 and 1999 on managing a biotech investment firm, Paramount Capital/Aries Funds, but in 1999, Michael Weiss left to create his own biotech company, ACCESS Oncology (which would be acquired in 2004 by Keryx Biopharmaceuticals (KERX)).
In the meantime, Lindsay Rosenwald continued to work at Aries, which became one of the most prolific incubators of new biotech start-up up until the financial crisis of 2007-2008. As Michael Weiss also left Keryx Biopharmaceuticals, where he had worked after the acquisition of ACCESS Oncology, in 2009, both decided to join their forces to create a new hedge fund, which benefited from over two decades of experience of both partners in the biotech space.
Due to the biotech-focused background of both of its founders, Opus Point Partners is mainly invested in the biotech industry, which accounts for over 90% of its equity portfolio. In addition, because of Michael Weiss’ and Dr. Lindsay Rosenwald’s expertise in the field, they take an activist approach, i.e. they serve on the board of directors of several companies, such as Avenue Therapeutics Inc (ATXI), where Dr. Rosenwald is the Executive Chairman, Mustang Bio, Inc. (MBIO), where Michael Weiss serves as Chairman of the Board, and Checkpoint Therapeutics Inc (CKPT), where Mr. Weiss is the Executive Chairman. In addition, Dr. Rosenwald is the Chairman and CEO of Fortress Biotech Inc (FBIO), and Mr. Weiss serves as the Executive Chairman and CEO of TG Therapeutics Inc (TGTX).